ADT
About: ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name. The company segments include Consumer and Small Business (CSB).
Employees: 12,800
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 5 (+3) [Q1 2025]
117% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 42
99% more repeat investments, than reductions
Existing positions increased: 153 | Existing positions reduced: 77
15% more funds holding
Funds holding: 315 [Q4 2024] → 361 (+46) [Q1 2025]
10% more capital invested
Capital invested by funds: $5.63B [Q4 2024] → $6.2B (+$568M) [Q1 2025]
2.92% less ownership
Funds ownership: 95.65% [Q4 2024] → 92.73% (-2.92%) [Q1 2025]
24% less call options, than puts
Call options by funds: $18.1M | Put options by funds: $24M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
11%
upside
Avg. target
$9
11%
upside
High target
$9
11%
upside
2 analyst ratings
0 positive
0%
2 neutral
100%
0 negative
0%
RBC Capital Ashish Sabadra | 11%upside $9 | Sector Perform Reiterated | 21 Apr 2025 |
Barclays Manav Patnaik | 11%upside $9 | Equal-Weight Upgraded | 4 Apr 2025 |
Financial journalist opinion
Neutral
Business Wire
2 weeks ago
ASCO 2025: Phase III ARANOTE Post-hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus ADT
WHIPPANY, N.J.--(BUSINESS WIRE)--New post-hoc analyses from the investigational Phase III ARANOTE trial showed a clinically meaningful improvement in health-related quality of life (HRQoL) and delayed pain progression for metastatic castration-sensitive prostate cancer (mCSPC) patients treated with NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) versus patients treated with placebo plus ADT.1 The results will be presented at the 2025 American Society of Clinical Oncology (ASCO) A.
Positive
Seeking Alpha
1 month ago
Value Grab: Top 10 Stocks Under $10
Tariff turmoil and market downturn are creating buying opportunities for investors looking to capitalize on panic selling and fear. The US-China trade war and rotation from U.S. assets, declining USD, and uncertainty surrounding monetary policy have prompted many investors to de-risk and seek value. Some of the greatest value and growth opportunities can be found in diversifying portfolios with low-priced small-cap stocks - they can offer a bang for your buck.
Positive
24/7 Wall Street
1 month ago
4 Sizzling Buy-Rated Stocks Trading Under $10 With Massive Upside Potential
While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Neutral
GlobeNewsWire
1 month ago
ADT and Yale Introduce First-Ever Z-Wave User Credential Command Class Lock, Expanding Smart Home Security with Fingerprint Control
BOCA RATON, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT), the leader in smart home security solutions, in collaboration with Yale and the Z-Wave Alliance , today announced the launch of the Yale Assure Lock 2 Touch with Z-Wave for ADT+ .
Neutral
Business Wire
1 month ago
AUA 2025: New Data from Post-Hoc Analyses Shared on Ultra-Low Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Hormone-Sensitive Prostate Cancer Receiving NUBEQA® (darolutamide) plus Androgen Deprivation Therapy (ADT)
WHIPPANY, N.J.--(BUSINESS WIRE)--AUA 2025: New Data from Post-Hoc Analyses Shared on Ultra-Low PSA Response in Patients with mHSPC Receiving NUBEQA® (darolutamide) plus ADT.
Positive
Seeking Alpha
1 month ago
ADT: Solid Quarter Adds Confidence To Potential Growth Acceleration
I maintain a buy rating for ADT, driven by solid 1Q25 results, improved fundamentals, and promising growth prospects with the ADT+ platform. ADT's 1Q25 earnings showed 7% y/y revenue growth, margin expansion, and a record-low customer churn rate, highlighting the essential nature of its services. The ADT+ Translator and Trusted Neighbor features are strategic upgrades, enhancing customer retention and monetization, thus expanding ADT's addressable revenue base.
Positive
Zacks Investment Research
1 month ago
Are Investors Undervaluing ADT (ADT) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
Seeking Alpha
1 month ago
ADT Inc. (ADT) Q1 2025 Earnings Call Transcript
ADT Inc. (NYSE:ADT ) Q1 2025 Earnings Conference Call April 24, 2025 10:00 AM ET Company Participants Elizabeth Landers - Investor Relations Jim DeVries - Chairman, President & Chief Executive Officer Jeff Likosar - Chief Financial Officer Conference Call Participants Ronan Kennedy - Barclays George Tong - Goldman Sachs David Paige - RBC Capital Markets Peter Christiansen - Citigroup Yehuda Silverman - Morgan Stanley Operator Hello, and welcome to the ADT First Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise.
Positive
Zacks Investment Research
1 month ago
ADT (ADT) Surpasses Q1 Earnings and Revenue Estimates
ADT (ADT) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to earnings of $0.16 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
ADT Reports First Quarter 2025 Results
Continued strong financial results with record recurring monthly revenue and customer retention GAAP operating cash flows up 28%, Adjusted Free Cash Flow including interest rate swaps up 105% Returned $445 million to shareholders through share repurchases and dividends On track to achieve full year 2025 guidance metrics BOCA RATON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT) today reported results for the first quarter of 2025.
Charts implemented using Lightweight Charts™